#1 Clinical Trials Search in Europe

Gliclazide

This article examines the use of Gliclazide, an important medication for treating type 2 diabetes, in various clinical trials. These studies aim to better understand Gliclazide’s effects, compare it to other diabetes drugs, and explore potential new applications to improve patient care and outcomes.

Table of Contents

What is Gliclazide?

Gliclazide is a medication used to treat type 2 diabetes mellitus. It belongs to a class of drugs called sulfonylureas[1]. Gliclazide is known by various brand names, including Diamicron, Sun-Glizide, and Benil[2][3]. This medication is typically prescribed when diet and exercise alone are not sufficient to control blood sugar levels in people with type 2 diabetes.

How Gliclazide Works

Gliclazide works by stimulating the pancreas to produce more insulin, which is the hormone responsible for regulating blood sugar levels. Specifically, it binds to and inhibits the ATP-sensitive potassium (KATP) channel in the pancreatic beta cells[2]. This action leads to an increase in insulin secretion, which helps lower blood glucose levels in people with type 2 diabetes.

Conditions Treated with Gliclazide

The primary condition treated with gliclazide is type 2 diabetes mellitus. This is a chronic condition characterized by high blood sugar levels due to the body’s inability to properly use insulin or produce enough of it[1][3]. Gliclazide is often prescribed when lifestyle changes alone (such as diet and exercise) are not sufficient to control blood sugar levels.

Dosage and Administration

Gliclazide is typically taken orally in tablet form. The dosage can vary depending on the individual patient’s needs and response to treatment. Some common dosage forms include:

  • Gliclazide 30 mg modified-release (MR) tablets, taken once daily[4]
  • Gliclazide 80 mg tablets, which may be taken once or twice daily[5]

It’s important to note that the dosage should be determined by a healthcare professional and may be adjusted based on the patient’s blood sugar levels and response to treatment. In some cases, the dose may be increased gradually to achieve optimal blood sugar control[3].

Effectiveness of Gliclazide

Gliclazide has been shown to be effective in lowering blood glucose levels in people with type 2 diabetes. Its effectiveness is often measured by changes in glycated hemoglobin (HbA1c) levels, which reflect average blood sugar control over the past 2-3 months[3]. Clinical trials have demonstrated that gliclazide can significantly reduce HbA1c levels, fasting plasma glucose, and postprandial (after-meal) glucose levels[3].

Potential Side Effects

Like all medications, gliclazide can cause side effects in some people. The most common and important side effect to be aware of is hypoglycemia, which is when blood sugar levels drop too low. Symptoms of hypoglycemia can include:

  • Sweating
  • Shakiness
  • Dizziness
  • Confusion
  • Hunger

It’s important to be aware of these symptoms and know how to manage them. Other potential side effects may include weight gain and gastrointestinal disturbances[3].

Drug Interactions and Precautions

Gliclazide may interact with other medications, potentially affecting its effectiveness or increasing the risk of side effects. It’s important to inform your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements. Some medications that may interact with gliclazide include other diabetes medications, certain antibiotics, and drugs that affect liver function[6].

Ongoing Research and Future Perspectives

Research on gliclazide is ongoing, with studies exploring its potential benefits beyond blood sugar control. Some areas of investigation include:

  • Effects on vascular function in people with type 2 diabetes[7]
  • Potential synergistic effects with other diabetes medications[1]
  • Genetic factors that may influence response to gliclazide treatment[2]

These ongoing studies may provide new insights into the optimal use of gliclazide and its potential benefits for people with type 2 diabetes.

Aspect Details
Main Focus Investigating Gliclazide’s effectiveness, safety, and potential new applications in type 2 diabetes treatment
Study Designs Randomized controlled trials, crossover studies, bioequivalence studies
Comparison Drugs Dapagliflozin, Metformin, Cabergoline, Henagliflozin, Dorzagliatin
Key Outcomes Measured Blood glucose levels, HbA1c, insulin secretion, vascular function, kidney function markers
Special Considerations Genetic influences on drug response, combination therapy effects, impact on cognitive function
Potential Benefits Improved glycemic control, vascular health, kidney function protection
Safety Monitoring Regular follow-ups, adverse event tracking, dose adjustments as needed

FAQ

  • What is Gliclazide and how does it work? Gliclazide is a medication used to treat type 2 diabetes. It belongs to a class of drugs called sulfonylureas. Gliclazide works by stimulating the pancreas to produce more insulin, which helps lower blood sugar levels.
  • How is Gliclazide being studied in clinical trials? Gliclazide is being studied in various ways, including comparing its effectiveness to other diabetes medications, examining its effects on vascular function, investigating its interaction with other drugs, and exploring its potential benefits for kidney function in diabetes patients.
  • Are there any unique features of Gliclazide compared to other diabetes medications? Yes, some studies suggest that Gliclazide may have different effects based on a person's genetic makeup. For example, one trial is investigating how variations in the KCNJ11/ABCC8 genes might influence a patient's response to Gliclazide compared to other sulfonylureas.
  • What are some potential benefits of Gliclazide being explored in trials? Trials are exploring Gliclazide's potential benefits on vascular function, its effectiveness in combination with other diabetes medications, and its possible protective effects on kidney function in people with type 2 diabetes.
  • How long do typical clinical trials involving Gliclazide last? The duration of Gliclazide trials varies depending on the study objectives. Some trials last a few weeks, while others may continue for several months to a year to assess long-term effects and safety.

Ongoing Clinical Trials on Gliclazide

  • Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on the Effectiveness and Safety of Gliclazide MR, Dapagliflozin, and Metformin for Patients with Type 2 Diabetes Not Well Controlled with Dapagliflozin

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Hungary Latvia Lithuania Poland

Glossary

  • Type 2 Diabetes Mellitus (T2DM): A chronic condition that affects the way your body processes blood sugar (glucose), characterized by high blood sugar levels due to insulin resistance or insufficient insulin production.
  • Sulphonylurea: A class of medications used to treat type 2 diabetes that work by stimulating the pancreas to produce more insulin.
  • Gliclazide: A type of sulphonylurea medication used to treat type 2 diabetes by increasing insulin production in the pancreas.
  • Metformin: A common first-line medication for type 2 diabetes that helps reduce blood sugar levels by improving insulin sensitivity.
  • HbA1c: Glycated hemoglobin, a blood test that provides information about a person's average blood sugar levels over the past 2-3 months.
  • Insulin: A hormone produced by the pancreas that regulates blood sugar levels by allowing cells to use glucose from the bloodstream.
  • Bioequivalence: The property of two drug products having the same biological effect in terms of the rate and extent of drug absorption.
  • Vascular function: The ability of blood vessels to perform their roles in circulation, including dilation and constriction to regulate blood flow.
  • Incretin effect: The enhanced insulin secretion that occurs when glucose is taken orally compared to when it is administered intravenously.
  • Endothelial function: The health and performance of the inner lining of blood vessels, which plays a crucial role in vascular health.
  • Flow-mediated dilation (FMD): A non-invasive test to assess endothelial function by measuring how blood vessels dilate in response to increased blood flow.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • eGFR: Estimated Glomerular Filtration Rate, a measure of kidney function that estimates how well the kidneys are filtering blood.

References

  1. https://clinicaltrials.gov/study/NCT03705195
  2. https://clinicaltrials.gov/study/NCT02201602
  3. https://clinicaltrials.gov/study/NCT01022762
  4. https://clinicaltrials.gov/study/NCT03313661
  5. https://clinicaltrials.gov/study/NCT02643329
  6. https://clinicaltrials.gov/study/NCT03467945
  7. https://clinicaltrials.gov/study/NCT02610088